When Ozempic and Wegovy burst into the cultural conversation as weight-loss drugs, most observers focused on the dramatic transformations. But the scientific story behind GLP-1 receptor agonists is far richer and more consequential — researchers and clinicians are discovering that these drugs appear to exert powerful protective effects across multiple organ systems, potentially reshaping medicine’s approach to conditions far beyond obesity.
What GLP-1 Drugs Actually Do
GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It signals the pancreas to release insulin, tells the brain to reduce appetite, and slows stomach emptying. Semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) are synthetic versions that bind to GLP-1 receptors far longer than the natural hormone, providing sustained metabolic effects. Clinical trials show average body weight reductions of 15 to 22 percent — but the drugs’ mechanisms appear to extend well beyond appetite suppression.
Heart Disease: The SELECT Trial
The landmark SELECT trial found that semaglutide reduced major cardiovascular events — heart attack, stroke, and cardiovascular death — by 20 percent in people with obesity and established heart disease, regardless of how much weight they lost. This was a bombshell finding suggesting direct cardioprotective effects: reducing inflammation, improving endothelial function, and possibly stabilizing arterial plaques. The FDA subsequently approved Wegovy specifically for cardiovascular risk reduction — a first for an obesity drug.
Kidneys, Liver, and the Brain
The FLOW trial demonstrated semaglutide reduced kidney disease progression and kidney-related death by 24 percent in patients with type 2 diabetes and chronic kidney disease. For metabolic dysfunction-associated steatohepatitis (MASH) — fatty liver disease that can progress to cirrhosis — semaglutide trials show significant resolution of liver inflammation and fibrosis. Perhaps most surprisingly, patients on semaglutide report reduced cravings for alcohol, nicotine, and compulsive behaviors, prompting active clinical trials for alcohol use disorder and opioid cravings. A phase 2 trial for early Alzheimer’s disease is also underway, motivated by the drug’s anti-inflammatory effects in the brain.
The Access Problem
Enthusiasm for GLP-1 drugs runs headlong into a formidable barrier: Wegovy lists at over $1,300 per month in the US without insurance coverage, which remains inconsistent. The patients who could benefit most are often least able to afford the drugs. Compounding pharmacies that briefly offered cheaper semaglutide during FDA shortage periods have seen that pathway tighten. Generic versions are years away. GLP-1 drugs may be the most consequential class of medications since statins transformed cardiovascular medicine — but delivering their full public health potential requires solving the access equity problem first.
